We narrowed to 7,670 results for: URE

#124651-AAV9

Ready-to-use AAV9 particles produced from pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 (#124651). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of ChrimsonR fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Aug. 27, 2019

Academic Institutions and Nonprofits only

#112010-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 2, 2019

Academic Institutions and Nonprofits only

#137161-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet (#137161). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet plasmid DNA. nEF-driven expression of ChRmine-oScarlet in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Oct. 14, 2020

Academic Institutions and Nonprofits only

#121675-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

May 31, 2019

Academic Institutions and Nonprofits only

#111262-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6s (#111262). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

May 8, 2019

Academic Institutions and Nonprofits only

#124603-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 (#124603). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 plasmid DNA. EF1a-driven, Cre-dependent expression of ChrimsonR fused to mRuby2 fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Sept. 26, 2019

Academic Institutions and Nonprofits only